These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30238318)

  • 1. Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis.
    Ellul P; Delorme R; Cortese S
    CNS Drugs; 2018 Dec; 32(12):1103-1112. PubMed ID: 30238318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
    Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
    Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.
    Newall H; Myles N; Ward PB; Samaras K; Shiers D; Curtis J
    Int Clin Psychopharmacol; 2012 Mar; 27(2):69-75. PubMed ID: 21979790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.
    Pringsheim T; Lam D; Ching H; Patten S
    Drug Saf; 2011 Aug; 34(8):651-68. PubMed ID: 21751826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis.
    Schneider-Thoma J; Efthimiou O; Bighelli I; Dörries C; Huhn M; Krause M; Reichelt L; Röder H; Furukawa TA; Davis JM; Leucht S
    Lancet Psychiatry; 2019 Sep; 6(9):753-765. PubMed ID: 31320283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
    Praharaj SK; Jana AK; Goyal N; Sinha VK
    Br J Clin Pharmacol; 2011 Mar; 71(3):377-82. PubMed ID: 21284696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials.
    Zheng W; Li XB; Tang YL; Xiang YQ; Wang CY; de Leon J
    J Clin Psychopharmacol; 2015 Oct; 35(5):499-509. PubMed ID: 26280837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
    Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
    J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
    Arman S; Sadramely MR; Nadi M; Koleini N
    Saudi Med J; 2008 Aug; 29(8):1130-4. PubMed ID: 18690305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis.
    Siskind DJ; Leung J; Russell AW; Wysoczanski D; Kisely S
    PLoS One; 2016; 11(6):e0156208. PubMed ID: 27304831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
    Wu RR; Zhao JP; Jin H; Shao P; Fang MS; Guo XF; He YQ; Liu YJ; Chen JD; Li LH
    JAMA; 2008 Jan; 299(2):185-93. PubMed ID: 18182600
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.